Potential Drug Interactions in Psychiatric Patients Undergoing Pangenotypic Therapy for Hepatitis C Virus Infection

TL;DR

This paper examines drug interactions between hepatitis C treatments and psychiatric medications, highlighting the importance of managing these interactions in patients with mental disorders.

Contribution

The paper provides a focused analysis of drug-drug interactions specific to pangenotypic hepatitis C therapies and psychotropic drugs.

Findings

Pangenotypic DAAs and psychotropic medications may interact due to overlapping metabolic pathways.

These interactions can affect the efficacy of both psychiatric and antiviral treatments.

Understanding these interactions is essential for managing patients with comorbid mental disorders and HCV.

Abstract

Over the past decade, significant progress has been made in the treatment of chronic hepatitis C virus (HCV) infection. The introduction of direct-acting antivirals (DAAs) has revolutionized the treatment of HCV infection, offering nearly 100% efficacy. Furthermore, additional therapeutic regimens with pangenotypic efficacy have been registered. These drugs are also characterized by a few adverse events and good treatment tolerance. As DAA therapy is now accessible to virtually all patients, including those with multimorbidity who often take multiple medications, drug interactions (DDIs) have become a significant clinical challenge. One of the groups of patients who are frequently infected with HCV is those with mental disorders. Due to frequently overlapping metabolic pathways, DDIs can occur, affecting the effectiveness of both psychiatric and antiviral therapy. Knowledge of these interactions is crucial in these cases and influences patient management. This paper discusses the most significant interactions between pangenotypic DAA regimens and psychotropic medications.

Figures